Table 3.
Amino Acid Substitutions in Nsp12 Detected Postbaseline
| Participants, No. (% out of Participants With Baseline and Postbaseline Sequencing Data Available)a | |||||||
|---|---|---|---|---|---|---|---|
| Mild/Moderate Disease | Severe Disease | Any Disease Severity | Total | ||||
| RDV | Placebo | RDV | Placebo | RDV | Placebo | ||
| Participants with baseline and postbaseline sequencing datab | 4 | 2 | 27 | 28 | 31 | 30 | 61 |
| No substitution | 2 (50.0) | 1 (50.0) | 17 (63.0) | 18 (64.3) | 19 (61.3) | 18 (60.0) | 37 (60.7) |
| Any substitution | 2 (50.0) | 1 (50.0) | 10 (37.0) | 10 (35.7) | 12 (38.7) | 12 (40.0) | 24 (39.3) |
| A16V | 1 (25.0) | 0 | 0 | 0 | 1 (3.2) | 0 | 1 (1.6) |
| T20T/1 | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| G44G/V | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| F56F/S | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| K59K/N | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| D60D/H | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| A97A/S | 0 | 1 (50.0) | 0 | 0 | 0 | 1 (3.3) | 1 (1.6) |
| A125A/T | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| A176A/V | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| P227P/Lc | 1 (25.0) | 0 | 0 | 1 (3.6) | 1 (3.2) | 1 (3.3) | 2 (3.3) |
| D291D/N | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| A311A/E | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| A311A/T | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| V315V/F | 0 | 1 (50.0) | 0 | 0 | 0 | 1 (3.3) | 1 (1.6) |
| P323P/L | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| T324T/I | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| G345G/V | 0 | 1 (50.0) | 0 | 0 | 0 | 1 (3.3) | 1 (1.6) |
| V359V/I | 0 | 0 | 1 (3.7)d | 0 | 1 (3.2)d | 0 | 1 (1.6) |
| A382A/V | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| N403N/I | 0 | 1 (50.0) | 0 | 0 | 0 | 1 (3.3) | 1 (1.6) |
| A423A/V | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| S425S/P | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| G427G/V | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| Q444Q/H | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| Y483Y/H | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| S501L | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| Q524Q/* | 1 (25.0) | 0 | 0 | 0 | 1 (3.2) | 0 | 1 (1.6) |
| T567T/I | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| D684D/N | 1 (25.0) | 0 | 0 | 0 | 1 (3.2) | 0 | 1 (1.6) |
| T701T/M | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| L707L/F | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| Y719Y/C | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| R733R/I | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| V764V/L | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| A771A/P | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| V792I | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| C799C/F | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| G823G/C | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
| P830P/S | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| P832P/S | 0 | 0 | 0 | 1 (3.6) | 0 | 1 (3.3) | 1 (1.6) |
| F843F/L | 0 | 0 | 1 (3.7) | 0 | 1 (3.2) | 0 | 1 (1.6) |
Abbreviations: RDV, remdesivir; SpO2, peripheral oxygen saturation.
aSevere disease was defined as requiring mechanical ventilation, requiring oxygen, SpO2 ≤94% on room air, or tachypnea (respiratory rate ≥24 breaths/minute). Mild/moderate disease was defined as having SpO2 >94% and respiratory rate <24 breaths/minute without supplemental oxygen.
bThis table lists Nsp12 substitutions emerged in the RDV and placebo arms with >80th percentile of cumulative viral shedding and <20th percentile of cumulative viral shedding.
cP227L was observed as a full mutant in 1 participant in the placebo arm and as a mixture with wild type in 1 participant in the RDV arm.
dIn the RDV arm, V359V/I and L707L/F were observed in 1 participant with <20th percentile of cumulative viral shedding. The other substitutions in the RDV arm were observed in participants with >80th percentile of cumulative viral shedding.